Saran Saund, Chief Business Officer, Oncotelic.
May 4th, 2021
Oncotelic Therapeutics will be working with Chopra Foundation and Heart Care Foundation to provide COVID-19 relief for India, including medicines and oxygen concentrators.
Medicines will include PulmoHeal™, created by Oncotelic and our Indian partner – Windlas Biotech Pvt. Ltd. PulmoHeal™ is already available over-the-counter (OTC) in India on e-commerce platforms and pharmacies. PulmoHeal™ has been shown to improve long term respiratory recovery from COVID-19 and possibly from overuse of supplement oxygen- an area of unmet medical needs.
The deployment of PulmoHeal™ on a large scale will also enable the use of its Post Marketing Survey platform (PMS), which includes the cough artificial intelligence (AI) platform. Put together, PulmoHeal™ will enable the collection of data on the progression of patients’ response to COVID with its use, as well as other COVID medications. India is caught in a ferocious second wave of the coronavirus pandemic, with the Indian authorities reporting in excess of 400,000 new COVID-19 cases per day. Every one of these patients are participating in an uncontrolled clinical experimentation since there is no proven treatment protocol for COVID-19, except for dexamethasone. It is our objective to leverage our crowd source PMS platform to gather performance data across the multitude of experimental therapeutics being deployed on the Indian community such as Ivermectin, Vitamins, and Ayurvedic drugs. The goal is to arrive at definitive answer as to what is working and what is not working.
Heart Care Foundation of India has been involved in providing free oxygen concentrators to those patients whose oxygen levels are dropping and who are not able to find a bed or resource in hospitals. This humanitarian deployment of PulmoHeal™, together with oxygen, should be synergistic in both the immediate and long-term recovery of COVID-19 patients in India